Home
overview
The world-wide prevalence of asthma is now reaching epidemic proportions afflicting over 50 million individuals globally and continues to escalate at an alarming rate. In addition, asthma is a major cost to healthcare systems comprising over 1% of the total healthcare bill in the USA - the highest for any single disease.

For these reasons drug developers and physicians have been prompted to review current treatments and improve therapeutic approaches to asthma management. Traditionally asthma medicines have helped the symptoms, but have done nothing for the underlying inflammation associated with the disease. It has now been recognised that the symptoms of asthma would be better treated with molecules that actually block particular steps within the cellular inflammatory cascade in conjunction with improved drug delivery systems.

With this knowledge in mind, our challenge at SMi was to assemble key industry peers within asthma research that would provide pertinent and up-to-date information on the key innovations within this exciting field. As you can see from this brochure we have more than achieved our goal.

Why should you attend this event? This is your unique opportunity to meet senior industry executives and seek their advice and opinions. This essential conference will feature the development and latest advancements of revolutionary therapeutic agents designed for the treatment of asthma. Covering market trends, new combination therapies, therapeutic anti-bodies, targeting of specific cytokines, pharmacogenetics, pharmacoepidemiology and delivery problems - this event is imperative for all pharmaceutical executives and researchers working in this fast-moving area of drug development.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Prof Paul Nicholls

Prof Paul Nicholls, Professor of Pharmacology, Cardiff University

9:10 THE NATURAL HISTORY OF ASTHMA

Dr Kulasiri Gunawardena

Dr Kulasiri Gunawardena, Director, Clinical Research, Chiltern International

  • The problem of asthma
  • Defining asthma
  • Relationship of atopy, airway hyper-responsiveness (AHR) and airway inflammation to clinical asthma
  • Natural history of atopy, AHR, airway inflammation
  • Influence of airway remodelling on airflow obstruction and airway hyper-responsiveness
  • Relevance of these to the design of clinical trials in asthma
  • 9:40 STRATEGIC OVERVIEW OF THE ASTHMA MARKET 2001-2007

    Anne Delaney

    Anne Delaney, Head, Immune Disorders & Inflammation, Datamonitor

  • The global asthma market
  • Patient education and compliance; Pipeline analysis
  • Meeting the unmet needs of asthma
  • Environmental factors influencing the future asthma market
  • Market forecasts to 2007
  • Strategies for success in a competitive environment
  • 10:20 FROM GENES TO ASTHMA THERAPEUTICS

    Douglas Hay

    Douglas Hay, Group Director, SmithKline Beecham

  • Identification of targets: too many targets too little time?
  • Target identification versus target validation
  • Value and limitations of animals. Don’t forget the patient!
  • Is quicker better?
  • From target to patentable ligand-reverse pharmacology
  • Diagnostics and molecular medicine - the way forward?
  • 11:00 Morning Coffee

    11:20 CPG DNA AND ASTHMA

    Dr Joel Kline

    Dr Joel Kline, Associate Professor, Coley Pharmaceutical Group

  • CpG oligodeoxynucleotides are effective in preventing manifestations of asthma in a murine model, including IgE induction, airway eosinophilia, and bronchial hyperreactivity
  • As immunotherapy, CpG DNA can downregulate inflammatory responses in established asthma CpG DNA is effective when administered through a variety of routes, including parenteral, transmucosal, and oral
  • Preliminary human studies are underway in humans
  • 12:00 THE ROLE OF INTERFERON-ALPHA IN ASTHMA

    Prof Albrecht Bufe

    Prof Albrecht Bufe, Department Leader, Experimental Pneumology & Clinical Research Group - ‘Viral Infection and Chronic Pulmonary Disease’, Ruhr-University Bochum

  • IFN-alpha as a linker molecule between viral infection and atopic asthma
  • Molecular regulation of IFN-alpha in viral infection and atopic immune response
  • IFN-alpha as a diagnostic tool for asthma? First study results
  • Phase 1 and 2 studies for combined treatment with IFN-alpha and allergen immunotherapy in asthma
  • 12:40 Networking Lunch

    14:00 TARGETING IL-9 DURING THE INFLAMMATORY RESPONSE

    Dr Kenneth Holroyd

    Dr Kenneth Holroyd, Senior Vice President, Clinical Research & Regulatory Affairs, Magainin

  • Employment of functional genomics to discover therapeutic targets for asthma and allergy
  • The role of IL-9 in asthma
  • Preclinical research programme: IL-9 acts directly and specifically to promote lung inflammation in asthma
  • Development and commercialisation of an IL-9 antibody for human asthma treatments
  • 14:40 SELECTING AN EFFECTIVE DELIVERY TECHNOLOGY

    Dr Mark Parry Billings

    Dr Mark Parry Billings, Director, Research & Development, Innovata

  • Overview of delivery options and recent advances
  • Selection of the optimal technology
  • Key challenges in development and registration
  • Future perspectives
  • 15:20 Afternoon Tea

    15:40 RELENZA - INHALED ANTIVIRAL THERAPY FOR INFLUENZA

    Dr Dereck Tait

    Dr Dereck Tait, Clinical Programme Head, GlaxoWellcome

  • What is Relenza?
  • Mechanism of action: targeted delivery
  • Preclinical studies; Clinical data to date
  • Clinical impact of influenza in asthmatic patients
  • Socioeconomic impact of influenza - global burden of illness and impact on patients with asthma
  • Predicting the impact of Relenza on future asthma management
  • 16:20 THE FUTURE FOR INHALATION DEVICES

    Dr Paul Wright

    Dr Paul Wright, Associate Director, Product Development, AstraZeneca

  • Complexity vs simplicity
  • Device vs formulation
  • Systemic vs topical
  • Environmental factors
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Networking Drinks Reception

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Prof Fan Chung

    Prof Fan Chung, Professor of Respiratory Medicine, Imperial College School of Medicine

    9:10 PHARMACOGENETICS AND PHARMACOEPIDEMIOLOGY OF ASTHMA

    Dr Joan Soriano

    Dr Joan Soriano, Principal Epidemiologist, Worldwide Epidemiology, GlaxoWellcome

  • Drivers of pharmacogenetics, pharmacogenomics and pharmacoepidemiology
  • Asthma pharmacogenetic initiatives and new targets
  • Asthma trials to date
  • From the gene to the population
  • Human genetics and the future of healthcare
  • 9:40 GENETIC AND GENOMIC APPROACHES TO UNDERSTANDING ASTHMA

    Gary Peltz

    Gary Peltz, Head, Genetics & Genomics, Roche Bioscience

  • Novel analytic methods for murine experimental genetic model of asthma
  • Accelerated identification of genetic loci using genetic and genomic technologies
  • Genetic regulation of innate and adaptive immune system interface
  • 10:20 COMMERCIALISING NOVEL AND COMPLEX ASTHMA THERAPIES

    Dr Rodney Hornbake

    Dr Rodney Hornbake, Senior Vice President & Chief Medical Officer, Gentiva Health Services

  • Navigating health plan and US governmental payment policies
  • Preparing payers for the launch of new therapies
  • Informing and energising patient communities
  • Building clinical support services for physicians and patients
  • Assisting physicians in developing clinical programs
  • Emerging American health policies that will impact marketing and distribution strategies
  • 11:00 Morning Coffee

    11:20 DEVELOPMENT OF MASTER ALLERGIC MEDIATORS

    Prof Heinz Werner Radtke

    Prof Heinz Werner Radtke, Executive Vice President, Research & Development, Byk Gulden

  • The aim: development of non-steroidal anti-inflammatory treatment in asthma and chronic bronchitis
  • PDE inhibitors: molecular mechanism of action
  • Clinical data to date
  • Predicted impact on asthma therapeutics
  • 12:00 IDENTIFICATION OF NOVEL ASTHMA GENES

    Dr Nick Lench

    Dr Nick Lench, Programme Manager, Inflammation Biology,

  • Complex disease mapping
  • Linkage disequilibrium islands
  • SNPs vs haplotypes
  • Validation of novel genes
  • 12:40 Networking Lunch

    14:00 USING ADVANCED PULMONARY DELIVERY TECHNOLOGY TO IMPROVE CLINICAL OUTCOMES IN ASTHMA PATIENTS

    Dr Michael Placke

    Dr Michael Placke, Vice President, Business Development, Battelle Pulmonary Therapeutics

  • Factors affecting deposited dose patterns
  • Understanding patient use and misuse of inhalation devices
  • Improved fev1 responses while using lower overall doses of b-agonists
  • Approaches to controlling unwanted side effects
  • 14:40 ANTISENSE OLIGONUCLEOTIDES ATTENUATE DISEASE-RELATED PROTEINS

    Dr James Mannion

    Dr James Mannion, President & Chief Operating Officer, Epigenesis

  • Target validation technology
  • Respirable antisense oligonucleotide platform technology
  • Primate models of respiratory disease
  • Pharmacogenomics technology
  • Drugs in development: EPI-2010 (Durason™)
  • 15:20 Afternoon Tea

    15:40 THE ASTA MEDICA MULTI-DOSE DRY POWDER INHALER (DPJ)

    Dr Beatrix Fyrnys

    Dr Beatrix Fyrnys, Pharmaceutical Development & Head of Analytics, Asta Medica

  • Development objectives
  • Design and function
  • Robustness and reliability
  • Performance and efficacy characteristics
  • 16:20 ANTIGEN-SPECIFIC IMMUNOSUPPRESSION WITH Ii-KEY HYBRIDS

    Dr Robert Humphreys

    Dr Robert Humphreys, President & Chief Scientific Officer, Antigen Express

  • Antigenic peptides: spilled from MHC Class II by Ii-Key compounds
  • Hybrids of Ii-Key-spacer-antigenic epitope charge potently
  • Th2 or Th1 responses depending on method
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.